10-Q quarterly report · filed Nov 9, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 10-Q Quarterly Report

Short answer

Ginkgo Bioworks Holdings, Inc. (DNA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $28M (down 28.6% year over year) with net income of −$41M.

Q3 2026 key financials · XBRL

Revenue
$28M
−28.6% YoY · +37.5% QoQ
Net income
−$41M
+49.2% YoY · +12.3% QoQ
Operating margin
-157.5%
EPS (diluted)
−$0.62
+57.2% YoY · +16.2% QoQ

Source: XBRL data from the Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 10-Q on SEC EDGAR. USD.

Ginkgo Bioworks Holdings, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $27.7M, down $1.7M YoY from $29.4M, driven by reduced agriculture customer services
  • Operating margin (157.5%) vs (280.1%) YoY, based on operating losses of $43.6M and $82.3M
  • Cell engineering tools costs $1.8M vs $4.6M, benefiting from lower lab automation equipment expenses
  • Cash, equivalents and marketable securities $285.4M, sufficient through at least the next 12 months
  • Nine-month operating cash flow $(117.0)M, ATM proceeds $23.0M, expenditures expected to exceed revenue through next 12 months

Risk Factors

  • No material changes to 2025 Annual Report risk factors
  • Investment risk: potential loss of all or part of invested capital
  • Business risk: adverse effects on prospects, financial condition, or operating results
  • Carried-forward risk details unavailable in provided section

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Ginkgo Bioworks Holdings, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.